## 2 Results and Discussion
### Volatile Fingerprint: Terpene Profile and Secondary Lipid's Oxidation Products
\begin{table}
\begin{tabular}{l c c c c c c c c c c c c c c c c c c} \hline \hline  & (\% viral) & \multicolumn{1}{c}{**C**omabinoids Content (\(\mathrm{\text{ugg}}\))} & \multicolumn{1}{c}{**C**ombiologica Content (\(\mathrm{\text{ugg}}\))} & \multicolumn{1}{c}{**C**} & \multicolumn{1}{c}{**C**DD} & \multicolumn{1}{c}{**THC**} & \multicolumn{1}{c}{**C**NN**} & \multicolumn{1}{c}{**C**DG} & \multicolumn{1}{c}{**C**DG**} & \multicolumn{1}{c}{**C**DG**} & \multicolumn{1}{c}{**C**DG**} & \multicolumn{1}{c}{**C**DG**} & \multicolumn{1}{c}{**C**DG**} & \multicolumn{1}{c}{**C**DG**} & \multicolumn{1}{c}{**C**DG**} & \multicolumn{1}{c}{**C**DG**} \\ \hline
**Sampling** & **Duration from Delayed** & **Delayed** & **CDD** & **CDD** & **CDD** & **THC** & **CNN** & **CDG** & **CBD** & **Average** & \(\pm\)**\(\mathrm{\text{SD}}\) & **Average** & \(\pm\)**\(\mathrm{\text{SD}}\) & **Average** & \(\pm\)**\(\mathrm{\text{SD}}\) & **Average** & \(\pm\)**\(\mathrm{\text{SD}}\) \\
**Code** & **CDD** & **CDD** & **CDD** & **CDD** & **CDD** & **CDD** & **CDD** & **CDD** & **CDD** & **CDD** & **CDD** & **CDD** & **CDD** & **CDD** & **CDD** & **CDD** & **CDD** & **CDD** \\ \hline \hline O81,2 & 5.80 & 0.9 & 0.9 & 0.89 & 81.60 & 170.2 & 322 & 42 & 14 & 0.3 & 0.41 & - & 884 & 188 & 123 & 2.6 & 7 & 0.1 \\ O12,2 & 8.69 & 4 & 3.66 & 36.87 & 257.3 & 1908 & 13.5 & 208 & 1.5 & 716 & 5.1 & 62 & 0.3 & 1 & 0.0 & 12 & 0.1 \\ O13,2 & 12.1 & 1 & 079 & 287 & 241.7 & 146 & 10.5 & 40 & 2.8 & 16 & 1.1 & 5202 & 57.5 & 191 & 13.5 & 603 & 40.0 \\ O14,4 & 15.29 & 5 & 424 & 42.32 & 2396.8 & 0.01 & 0.0 & 3 & 0.2 & -0.01 & / & 6 & 0.3 & 196 & 11.1 & 19 & 1.1 \\ O15, 105,3 & 4 & 4 & 42.2 & 43.09 & 306.6 & 533 & 70 & 0.0 & 49 & -0.11 & / & 802 & 56.7 & 17 & 2.2 & 19 & 1.0 \\ O16,5 & 44 & 3 & 287 & 25.36 & 1008.9 & 536 & 125.4 & 481 & 17.0 & -0.01 & / & 152 & 5.4 & 29 & 1.0 & 8 & 0.3 \\ O17, 87 & 2.87 & 4 & 43.01 & 2601.8 & 1874.5 & 53 & 22.3 & 65 & 2.8 & -0.01 & / & 804 & 34.1 & 12 & 0.5 & 26 & 1.1 \\ O18, 35.1 & 3 & 4.66 & 398.36 & 301.3 & 695 & 54.1 & 42 & 4.8 & -0.01 & / & 753 & 58.6 & 47 & 3.2 & 21 & 1.7 \\ O19, 75.8 & 3 & 3.32 & 32.21 & 603.6 & 1607 & 341 & 34.5 & 7.3 & 23 & 0.5 & 88 & 1.9 & 25 & 0.5 & 6 & 0.1 \\ O10,10 & 23.89 & 4 & 496 & 485 & 106.9 & 557 & 11.8 & 79 & 1.7 & -0.01 & / & 774 & 16.4 & 58 & 1.2 & 23 & 0.5 \\ O11,1 & 7 & 7 & 024 & 185 & 46.9 & 56 & 1.3 & 7 & 0.3 & -0.01 & / & 634 & 23.3 & 32 & 12 & 18 & 0.7 \\ O12, 12 & 19.28 & 2 & 161 & 1278.4 & 1804 & 494 & 7.0 & 188 & 2.7 & 6 & 61 & 3662 & 54.6 & 107 & 1.5 & 49 & 1.4 \\ O13, 36.2 & 4 & 2.55 & 2444.48 & 239.8 & 56 & 56.2 & 1105 & 190.4 & 624 & 61.8 & 1299 & 2117.7 & 27 & 2.7 & 22 & 2.2 \\ O14, 38.1 & 5 & 3.09 & 2136.6 & 65.3 & 524 & 14.8 & 67 & 1.9 & 440 & 13.0 & 885 & 2847 & 388 & 101 & 226 & 6.1 \\ O15, 24.3 & 3 & 2.27 & 226.92 & 320.9 & -0.01 & / & 601 & 7 & 860 & 89.4 & 9 & 0.1 & -0.01 & / & 4 & 0.1 \\ \hline \hline \end{tabular}  
* CSD declared on labels,
* CSDprot (sum of CBD +0.877 \(\times\) CBDA).2 Reducfile oil extract prepared as generic product—detailed description of the method and its suitability was given previously by [PERSON] et al., 2018 (2).  
\end{table} 
Table 1: Cannabinoid content (expressed as % \(w/w\) and in \(\mathrm{\text{ug}}/\mathrm{\text{g}}\)) in investigated CBD oils (average \(\pm\) S.D., \(n\) = 2).